Linda Stocum, Associate Editor

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of March.

The company announced its collaboration with the American Academy of Dermatology on, “Pathways: Inclusivity in Dermatology,” to increase the number of practicing dermatologists in the Black, Latino, and Indigenous communities in medicine over the next 5 years.

This week's edition of the Mainstream Patients features stories about skin of color dermatology, a deep dive on hair loss, and more.

In this video interview, Peter A. Lio, MD, FAAD , discusses his presentation about pain-free dermatology at the 2022 American Academy of Dermatology annual meeting. We talk strategies, benefits, and more.

In this video interview, Adam J. Friedman, MD, FAAD, gives the highlights from his presentation at the 2022 American Academy of Dermatology annual meeting about dietary triggers in acne, providing evidence, and discussing how the idea came to be.

Zoe Diana Draelos, MD, FAAD, explains the method of using the color wheel to guide your patients nutrition to help skin, nails, and more.

In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."

ICYMI, this week we had stories on the latest coverage from the 2022 American Academy of Dermatology Annual meeting, coverage from the 18th Annual Skin of Color Symposium, and more.

In this video interview, we sit down with Natasha Atanaskova Mesinkovska, MD, PhD, FAAD, to discuss her 2022 AAD annual meeting presentation on alopecia areata. We dive into pipeline possibilities, what current treatments are missing, and more.

Vial Dermatology CRO announced that the associate professor of dermatology and rheumatology at Harvard Medical School and the vice chair of clinical trials and innovation at Brigham and Women's Hospital in Boston, Massachusetts, has joined its Scientific Advisory Board.

Laser hair removal was the most litigated.

In this video the OJM group talks about volatile markets and how to navigate investing in uncertain times.

This week's edition of the Mainstream Patients features stories about scalp acne, how to avoid skin irritation with a fitness tracker, and more.

ICYMI, this week we had stories on the genetics of acne, FDA warnings, and more.

A recent study examined the main reasons why patients in the United States seek care from dermatologists.

Zoe Diana Draelos, MD, sits down with Dermatology Times® to discuss her new book, Cosmetic Dermatology: Procedures and Practice, which will be releasing in the United States in April of 2022.

Almirall announced today that it will work with the University of Michigan to better understand disease drivers in hidradenitis suppurativa.

On March 14, the FDA released a warning for both consumers and health care providers against the use of the Renuvion/J-Plasma device (Apyx Medical) for dermal resurfacing or skin contraction.

This week's edition of the Mainstream Patients features stories about the benefits of rice water for hair, when skin care expires, and more.

ICYMI, this week we had stories on new data on pembrolizumab, Amyrt receiving a Complete Response Letter (CRL) for Oleogel-S10, and more.

Vial announced another addition to their CRO with David Pariser, MD, FACP, FAAD.

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.

This weekend, March 11-13, 2022, the San Diego Dermatology Symposium (SDDS) will be educating physicians in person. Everything from traditional topics like atopic dermatitis to rare disease such as Stevens-Johnson syndrome will be covered.

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.

The company was asked by the FDA to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

VYNE Therapeutics announced positive preclinical data of a lead BET inhibitor reducing melanocyte loss and key inflammatory biomarkers from an ex vivo skin model of vitiligo.

Merck announced that pembrolizumab led to significant improvement in distant metastasis-free survival (DMFS) compared to placebo as adjuvant therapy for patients with resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 trial.

This week's edition of the Mainstream Patients features stories about the benefits of face steaming for the skin, doctors that are making hair transplants more accessible to Black patients, and more.

ICYMI, this week we had stories on the trending skin care in February, a new podcast episode, and more.